查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718122

全球耳鼻喉治療市場按治療類型、患者年齡層、疾病類型、設備類型和最終用戶分類—預測至 2025-2030 年

ENT Disorder Treatment Market by Treatment Type, Patient Age Group, Disease Type, Device Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2023 年耳鼻喉治療市場價值將達到 307.2 億美元，到 2024 年將以 6.26% 的複合年成長率成長至 325.2 億美元，到 2030 年將達到 470 億美元。

主要市場統計數據
基準年2023年 307.2億美元
預計2024年 325.2億美元
預測年份 2030 470億美元
複合年成長率（%） 6.26%

在不斷變化的醫療保健領域，隨著醫療治療方法的創新、手術技術的複雜化以及技術干預的先進，耳鼻喉疾病的治療前景也在不斷發展。本報告深入探討了目前的市場動態和影響耳、鼻、喉部疾病治療通訊協定的新興趨勢。目前的治療策略受到挑戰傳統治療方法的臨床需求和以患者為中心的方法的驅動。因此，該分析揭示了治療類型、患者人口統計、疾病特異性、設備創新和最終用戶環境的見解。其根本目標是為產業相關人員提供可行的見解，指南他們的策略決策。

臨床研究、技術進步、監管改革和不斷變化的市場需求等複雜因素正在重新定義耳鼻喉疾病的治療方式。相關人員現在需要全面了解市場的多方面方面，包括細分和區域差異。透過詳細的調查方法和廣泛的資料集，本研究整合了主要趨勢和市場變化，提供了全面的概述。透過評估宏觀和微觀環境因素，本文提出的見解旨在使決策者能夠應對未來的挑戰並利用耳鼻喉疾病治療這一動態領域的新興機會。

改變耳鼻喉市場

近年來，耳鼻喉治療領域發生了顯著變化。數位健康、微創手術技術和新藥物療法的進步使該行業進入了以創新為醫療服務核心的時代。尖端診斷工具和即時監控系統的整合改善了患者的治療效果並簡化了臨床程序。

此外，遠端醫療和行動醫療應用的快速普及正在重塑患者獲得護理和維持治療依從性的方式，強調了個人化醫療解決方案的重要性。包括尖端手術機器人和精準醫療在內的技術進步進一步使臨床醫生能夠以前所未有的精度客製化干涉措施。這些因素的整合也促使監管機構協調標準並確保技術創新的安全性和有效性。研究機構和產業領袖之間的合作加速了科學突破向臨床實踐的轉化，並為新的治療模式奠定了基礎。

對聽力和平衡障礙的預防性護理和早期療育的轉變也為綜合服務提供開闢了新的途徑。重視病患教育和改善獲得專業耳鼻喉科服務的機會，明顯脫離了傳統的被動照護模式。這些轉變不僅重新定義了治療通訊協定，也為耳鼻喉科綜合永續醫療解決方案的時代奠定了基礎。

耳鼻喉治療市場的關鍵細分洞察

耳鼻喉治療市場的徹底細分分析揭示了層級構造，可以提供有關治療偏好和市場需求的詳細見解。基於治療類型的市場分析表明，傳統藥物療法、外科手術和創新療法明顯適用於各種患者。在藥物治療領域，以抗生素、抗組織胺藥物和類固醇為重點的研究展示了一種細緻的藥物介入方法。同時，切除術、切除術和鼓室成形術等外科手術強調了在複雜情況下提供的精確和專業護理。此外，言語和前庭復健治療等治療方法的出現凸顯了非侵入性復健治療作為補充治療方法的重要性。

按患者年齡層細分進一步凸顯了市場的異質性。該分析區分了成人、老年和兒科患者，每種患者都有自己的臨床要求和治療計劃。從疾病類型來看，耳鼻喉疾病分類明確。仔細觀察耳部疾病就會發現，梅尼爾氏症、外耳炎和中耳炎等疾病需要特別注意。另一方面，鼻部問題包括鼻息肉、鼻炎和鼻竇炎等疾病。咽頭炎和扁桃腺炎等與喉嚨相關的問題凸顯了與這些疾病相關的多種臨床挑戰。此外，基於設備類型的細分顯示市場對內視鏡、助聽器、聽力植入、鼻夾、聲帶假體等先進設備的依賴，這些設備對於促進準確診斷和有效干預至關重要。最後，最終用戶細分涵蓋廣泛的護理環境，包括門診手術中心、耳鼻喉和復健診所、居家照護機構和醫院。透過分析這些維度，細分洞察提供了影響產品開發和臨床決策流程的市場動態的詳細視圖。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球耳鼻喉疾病的發生率不斷上升，推動了對先進且有效的治療方案的需求。
      • 擴大全球醫療保健基礎設施，以增強獲得先進耳鼻喉護理的機會
      • 個人化、微創耳鼻喉治療方案的出現
    • 限制因素
      • 高級耳鼻喉科護理費用高且報銷選擇有限
    • 機會
      • 政府針對耳鼻喉相關疾病的積極措施和資金
      • 耳鼻咽喉科先進診斷工具和影像技術的開發
    • 任務
      • 新的耳鼻喉治療產品和治療方法的監管複雜性和冗長的核准流程；
  • 市場區隔分析
    • 治療類型：對於慢性病和解剖修復的需求，手術治療越來越受到青睞。
    • 患者年齡：與老齡化相關的症狀正在推動老年患者對耳鼻喉治療的需求
    • 疾病類型：耳鼻喉科治療感染疾病耳部疾病的需求不斷增加
    • 設備類型：聽力障礙人士擴大使用助聽器來放大聲音
    • 最終使用者：增加門診手術中心小手術的耳鼻喉護理量
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 耳鼻喉治療市場（依治療類型）

  • 製藥
    • 抗生素
    • 抗組織胺藥
    • 類固醇
  • 外科手術
    • 切除術
    • 切除術
    • 鼓室成形術
  • 治療方法
    • 語言治療
    • 前庭復健治療

第7章 耳鼻喉治療市場（依患者年齡層）

  • 成年患者
  • 老年患者
  • 兒科患者

第8章 耳鼻喉治療市場（依疾病類型）

  • 耳朵
    • 梅尼爾氏症
    • 外耳炎
    • 中耳炎
  • 鼻子
    • 鼻息肉
    • 鼻炎
    • 鼻竇炎
  • 喉
    • 咽頭炎
    • 扁桃腺炎

9. 耳鼻喉治療市場（依設備類型）

  • 內視鏡檢查
  • 助聽器
  • 聽力植入
  • 鼻夾板
  • 發聲假體

第 10 章 耳鼻喉治療市場（依最終使用者分類）

  • 門診手術中心
  • 診所
    • 耳鼻喉診所
    • 復健診所
  • 居家照護環境
  • 醫院

第 11 章 - 美洲耳鼻喉治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太耳鼻喉治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲耳鼻喉治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • ALK-Abello A/S
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Limited
  • Cochlear Limited
  • Covis Pharma GmbH
  • Demant A/S
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Fennec Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Integra Lifesciences Corporation
  • KARL STORZ SE & Co. KG
  • Medtronic PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Olympus Corporation
  • OptiNose, Inc.
  • Sanofi SA
  • Sensorion SA
  • Siemens Healthineers AG
  • Smith & Nephew PLC
  • Sonova Holding AG
  • Sound Pharmaceuticals, Inc.
  • Starkey Laboratories, Inc.
  • Stryker Corporation
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Widex A/S
  • WS Audiology A/S
  • Zounds Hearing
Product Code: MRR-757B1C9CAFAB

The ENT Disorder Treatment Market was valued at USD 30.72 billion in 2023 and is projected to grow to USD 32.52 billion in 2024, with a CAGR of 6.26%, reaching USD 47.00 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 30.72 billion
Estimated Year [2024] USD 32.52 billion
Forecast Year [2030] USD 47.00 billion
CAGR (%) 6.26%

In the ever-changing world of healthcare, the treatment landscape for ENT disorders is continuously evolving with innovations in medical therapies, refined surgical techniques, and advanced technological interventions. This report provides an in-depth exploration of the current market dynamics and emerging trends shaping treatment protocols for conditions affecting the ear, nose, and throat. Current therapeutic strategies are driven by both clinical demands and patient-centric approaches that challenge traditional treatment modalities. Consequently, this analysis uncovers insights into treatment types, patient demographics, disease specifics, device innovations, and end-user environments. The underlying objective is to furnish industry stakeholders with actionable insights to guide strategic decision-making.

The complex interplay of clinical research, technological advancements, regulatory reforms, and changing market needs has redefined how ENT disorders are managed. Stakeholders now require a comprehensive understanding of the multi-dimensional aspects of the market, including segmentation and regional variations. Through detailed research methodologies and expansive data sets, this study has synthesized key trends and market shifts to provide a thorough landscape overview. By assessing both macro and micro-environment factors, the insights presented here aim to empower decision-makers to navigate future challenges and capitalize on emerging opportunities in the dynamic world of ENT disorder treatment.

Transformative Shifts in the ENT Disorder Treatment Landscape

Recent years have witnessed remarkable transformations within the ENT disorder treatment sector. Advancements in digital health, minimally invasive surgical techniques, and emerging drug therapies have propelled the industry into an era where innovation is at the forefront of care delivery. The integration of cutting-edge diagnostic tools and real-time monitoring systems has improved patient outcomes and streamlined clinical procedures.

Moreover, the rapid adoption of telemedicine and mobile health applications has reshaped how patients access care and maintain treatment adherence, reinforcing the importance of personalized medical solutions. Technological evolution, including state-of-the-art surgical robotics and precision medicine, has further enabled clinicians to tailor interventions with unprecedented accuracy. The convergence of these factors has also spurred regulatory bodies to harmonize standards, ensuring that innovations are both safe and effective. Collaborative efforts between research institutions and industry leaders have facilitated the translation of scientific breakthroughs into everyday clinical practice, laying a new foundation for treatment paradigms.

The shift towards preventive care and early intervention in hearing and balance disorders has also opened new avenues for integrated service delivery. Emphasis on patient education, coupled with enhanced accessibility to specialized ENT services, marks a clear departure from traditional, reactive models of care. Together, these transformative changes are not only redefining treatment protocols but are also setting the stage for an era of integrative and sustainable healthcare solutions within the ENT sphere.

Key Segmentation Insights in the ENT Disorder Treatment Market

A thorough segmentation analysis of the ENT disorder treatment market reveals a layered structure that offers granular insights into treatment preferences and market demands. Market analysis based on treatment type shows that conventional medications, surgical procedures, and innovative therapies are deployed distinctly across various patient profiles. Within the medications segment, a focused study of antibiotics, antihistamines, and steroids illustrates a nuanced approach to pharmacological interventions. In parallel, surgical procedures such as mastoidectomy, stapedectomy, and tympanoplasty highlight the precision and specialty care delivered in complex scenarios. Additionally, the emergence of therapies like speech therapy and vestibular rehabilitation therapy underlines the importance of non-invasive, rehabilitative care as a complementary treatment modality.

Segmentation by patient age group further accentuates market heterogeneity. Analyses differentiate between adult, geriatric, and pediatric patients, each with unique clinical requirements and treatment timelines. When evaluating disease types, the market is distinctly categorized across ear, nose, and throat conditions. In-depth scrutiny of ear conditions reveals special attention to ailments such as Meniere's Disease, Otitis Externa, and Otitis Media, while nasal problems include conditions like nasal polyps, rhinitis, and sinusitis. Throat-related issues such as pharyngitis and tonsillitis underscore the diverse clinical challenges associated with these diseases. Moreover, segmentation based on device type illustrates the market's reliance on sophisticated instruments such as endoscopes, hearing aid devices, hearing implants, nasal splints, and voice prosthesis, all of which are essential in facilitating accurate diagnosis and effective intervention. Finally, end user segmentation encompasses a wide range of care settings, including ambulatory surgical centers, clinics with a focus on ENT and rehabilitation, homecare facilities, and hospitals. By dissecting these dimensions, the segmentation insights provide a detailed view of market dynamics that influence product development and clinical decision-making processes.

Based on Treatment Type, market is studied across Medications, Surgical Procedures, and Therapies. The Medications is further studied across Antibiotics, Antihistamines, and Steroids. The Surgical Procedures is further studied across Mastoidectomy, Stapedectomy, and Tympanoplasty. The Therapies is further studied across Speech Therapy and Vestibular Rehabilitation Therapy.

Based on Patient Age Group, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on Disease Type, market is studied across Ear, Nose, and Throat. The Ear is further studied across Meniere's Disease, Otitis Externa, and Otitis Media. The Nose is further studied across Nasal Polyps, Rhinitis, and Sinusitis. The Throat is further studied across Pharyngitis and Tonsillitis.

Based on Device Type, market is studied across Endoscopes, Hearing Aid Devices, Hearing Implants, Nasal Splints, and Voice Prosthesis.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, Homecare Settings, and Hospitals. The Clinics is further studied across ENT Clinics and Rehabilitation Clinics.

Key Regional Insights in the Global ENT Disorder Treatment Sector

Geographical analysis of the ENT disorder treatment market provides a nuanced understanding of regional trends and market potential. In the Americas, evolving healthcare policies and a growing emphasis on specialized treatment have laid the groundwork for innovative ENT interventions. This region continues to invest heavily in healthcare infrastructure and research activities, making it a primary area for early adoption of novel treatment technologies.

Across the Europe, Middle East & Africa region, the interplay of stringent regulatory standards and robust clinical research has spurred the adoption of advanced surgical techniques and treatment protocols. Here, a balanced focus on both traditional and emerging therapies creates a dynamic market environment where innovation is consistently encouraged. Moreover, public and private partnerships in these regions have led to the development of integrated healthcare solutions that cater to diverse patient populations.

In the Asia-Pacific region, rapid urbanization and improving access to healthcare services have significantly altered the public health landscape. Investments in medical device technologies, coupled with increasing awareness about ENT disorders, have spurred marked growth in the sector. Across these regions, continuous efforts to bridge the gap between basic care and advanced therapeutic interventions indicate a healthy competitive landscape that is fueling both market growth and improved patient outcomes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Driving Market Innovation

The competitive landscape of the ENT disorder treatment market is marked by the presence of several industry frontrunners who are steering innovation and market growth. Prestigious companies such as ALK-Abello A/S and AstraZeneca PLC have long established their leadership through pioneering research and extensive portfolios of therapeutic solutions. Major players like Bayer AG, Cipla Limited, and Cochlear Limited continue to revolutionize treatment methods with robust pipelines that address complex ENT disorders. Groundbreaking works by entities including Covis Pharma GmbH, Demant A/S, and Dr. Reddy's Laboratories further underscore the significance of collaborative research and cross-sector partnerships.

In addition, notable contributions from F. Hoffmann-La Roche Ltd., Fennec Pharmaceuticals Inc., and GlaxoSmithKline PLC have set new benchmarks in clinical efficacy and patient safety. Cutting-edge technologies from Integra Lifesciences Corporation, KARL STORZ SE & Co. KG, and Medtronic PLC drive advancements in device-based treatments, while companies like Merck & Co., Inc., Novartis AG, and Olympus Corporation continue to expand the horizon with innovative pharmaceutical and surgical offerings. The commitment to excellence is also evident in the strategic initiatives led by OptiNose, Inc., Sanofi SA, and Sensorion SA, complemented by technological leadership from Siemens Healthineers AG, Smith & Nephew PLC, and Sonova Holding AG. Further market insights are derived from dynamic contributions by Sound Pharmaceuticals, Inc., Starkey Laboratories, Inc., Stryker Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Viatris Inc., Widex A/S, WS Audiology A/S, and Zounds Hearing, all of which play pivotal roles in shaping the market's future through constant innovation and strategic investments.

The report delves into recent significant developments in the ENT Disorder Treatment Market, highlighting leading vendors and their innovative profiles. These include ALK-Abello A/S, AstraZeneca PLC, Bayer AG, Cipla Limited, Cochlear Limited, Covis Pharma GmbH, Demant A/S, Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Fennec Pharmaceuticals Inc., GlaxoSmithKline PLC, Integra Lifesciences Corporation, KARL STORZ SE & Co. KG, Medtronic PLC, Merck & Co., Inc., Novartis AG, Olympus Corporation, OptiNose, Inc., Sanofi SA, Sensorion SA, Siemens Healthineers AG, Smith & Nephew PLC, Sonova Holding AG, Sound Pharmaceuticals, Inc., Starkey Laboratories, Inc., Stryker Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Viatris Inc., Widex A/S, WS Audiology A/S, and Zounds Hearing. Actionable Recommendations for Industry Leaders

For stakeholders seeking sustainable growth in the ENT disorder treatment market, strategic foresight is imperative. Industry leaders should consider investing in interdisciplinary research that melds clinical practice with technological advancements. Prioritizing patient-centered care through the integration of digital monitoring systems and personalized treatment regimens can significantly enhance overall outcomes. A data-driven approach to market segmentation can further facilitate the optimization of product offerings and highlight areas of unmet clinical need.

Embracing collaborative partnerships across pharmaceutical, surgical, and rehabilitative sectors will not only streamline innovation but also drive efficiency in treatment delivery. Leaders are encouraged to leverage emerging trends in telemedicine and remote health monitoring, thereby broadening the accessibility of specialized care. Continuous education and training initiatives for healthcare professionals are equally important to ensure the seamless adoption of new technologies and methodologies. Furthermore, a proactive regulatory engagement strategy, underpinned by rigorous clinical data, can help navigate the complex compliance landscape while expediting market entry for innovative solutions.

By strategically aligning investment in research and development with market demands, industry decision-makers can forge pathways for sustainable success, ultimately benefiting patient outcomes and driving market expansion in a competitive global scenario.

Conclusion: A Future of Innovation in ENT Disorder Treatment

In conclusion, the evolution of the ENT disorder treatment landscape heralds a transformative era marked by innovative therapies, advanced surgical interventions, and enhanced patient-centric care. The comprehensive segmentation analysis spanning treatment type, patient age group, disease type, device type, and end user offers profound insights into the market drivers and operational challenges. Regional variations further illustrate the balanced growth potential across key markets in the Americas, Europe, Middle East & Africa, and Asia-Pacific.

The insights garnered from leading companies further validate the importance of cohesive, cross-disciplinary efforts in advancing both clinical outcomes and market performance. Such multidimensional analysis not only underscores the significance of continuous research and development but also highlights the importance of strategic alliances in enhancing global outreach. This report has provided a substantive foundation that empowers decision-makers to navigate the complexities of the market with confidence and optimism.

The future of ENT disorder treatment is undoubtedly poised for rapid advancements as it embraces technological innovation, integrated care models, and data-centric strategies. By converting these insights into actionable strategies, industry leaders can drive growth, improve patient care, and secure competitive advantages in a rapidly shifting healthcare landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of ENT disorders spurs need for advanced and effective treatment solutions
      • 5.1.1.2. Global expansion of healthcare infrastructure enhancing access to advanced ENT treatments
      • 5.1.1.3. Emergence of personalized and minimally invasive ENT treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of advanced ENT treatments and limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives and funding for ENT-related diseases
      • 5.1.3.2. Development of advanced diagnostic tools and imaging technologies in ENT care
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities and lengthy approval processes for new ENT treatment products and therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Increasing preference for surgical procedures for chronic conditions or anatomical repair needs
    • 5.2.2. Patient Age Group: Rising need for ENT disorder treatment among geriatric patients owing to aging-related condition
    • 5.2.3. Disease Type: Growing need for ENT disorder treatment to treat ear diseases caused by infections
    • 5.2.4. Device Type: Rising adoption of hearing aid devices by individuals with hearing loss to amplify sound
    • 5.2.5. End User: Increasing number of ENT disorder treatments in ambulatory surgical centers for minor procedures
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. ENT Disorder Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Medications
    • 6.2.1. Antibiotics
    • 6.2.2. Antihistamines
    • 6.2.3. Steroids
  • 6.3. Surgical Procedures
    • 6.3.1. Mastoidectomy
    • 6.3.2. Stapedectomy
    • 6.3.3. Tympanoplasty
  • 6.4. Therapies
    • 6.4.1. Speech Therapy
    • 6.4.2. Vestibular Rehabilitation Therapy

7. ENT Disorder Treatment Market, by Patient Age Group

  • 7.1. Introduction
  • 7.2. Adult Patients
  • 7.3. Geriatric Patients
  • 7.4. Pediatric Patients

8. ENT Disorder Treatment Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Ear
    • 8.2.1. Meniere's Disease
    • 8.2.2. Otitis Externa
    • 8.2.3. Otitis Media
  • 8.3. Nose
    • 8.3.1. Nasal Polyps
    • 8.3.2. Rhinitis
    • 8.3.3. Sinusitis
  • 8.4. Throat
    • 8.4.1. Pharyngitis
    • 8.4.2. Tonsillitis

9. ENT Disorder Treatment Market, by Device Type

  • 9.1. Introduction
  • 9.2. Endoscopes
  • 9.3. Hearing Aid Devices
  • 9.4. Hearing Implants
  • 9.5. Nasal Splints
  • 9.6. Voice Prosthesis

10. ENT Disorder Treatment Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Clinics
    • 10.3.1. ENT Clinics
    • 10.3.2. Rehabilitation Clinics
  • 10.4. Homecare Settings
  • 10.5. Hospitals

11. Americas ENT Disorder Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific ENT Disorder Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa ENT Disorder Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Aerin Medical secures USD 32.5 million in funding to revolutionize ENT disorder treatments with innovative technology
    • 14.3.2. Elevate ENT Partners acquired Atlantic ENT to strengthen its central Florida presence
    • 14.3.3. Apollo Hospitals launched an integrated Neuro-ENT Vertigo and balance disorders clinic to enhance care for vertigo and balance disorders in India
    • 14.3.4. Cilcare secures EUR 40 million to innovate treatments for underdiagnosed hearing loss
    • 14.3.5. Salvat pioneers Spanish pharmaceutical enhancement with FDA-approved BFS sterile drug manufacturing
    • 14.3.6. FDA approval of Neffy nasal spray a transformative breakthrough in anaphylaxis treatment options
    • 14.3.7. Takara Bio and Gap Junction Therapeutics partnered for advance AAV gene therapy for hereditary hearing loss
    • 14.3.8. Cilcare and Shionogi announce agreement to advance groundbreaking therapies for hidden hearing loss and tinnitus
    • 14.3.9. Integra LifeSciences acquisition of Acclarent transforms ENT disorder treatment landscape with innovative technologies
    • 14.3.10. Olympus Canada introduces innovative single-use ENT devices to streamline outpatient procedures
    • 14.3.11. XHANCE receives FDA approval for chronic rhinosinusitis without nasal polyps, transforming care for millions in the US
    • 14.3.12. Align ENT + Allergy partners with ear, nose, and throat specialists of Connecticut
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. GlaxoSmithKline PLC
    • 14.4.2. Medtronic PLC
    • 14.4.3. Olympus Corporation
    • 14.4.4. OptiNose US, Inc.

Companies Mentioned

  • 1. ALK-Abello A/S
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Cipla Limited
  • 5. Cochlear Limited
  • 6. Covis Pharma GmbH
  • 7. Demant A/S
  • 8. Dr. Reddy's Laboratories
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Fennec Pharmaceuticals Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Integra Lifesciences Corporation
  • 13. KARL STORZ SE & Co. KG
  • 14. Medtronic PLC
  • 15. Merck & Co., Inc.
  • 16. Novartis AG
  • 17. Olympus Corporation
  • 18. OptiNose, Inc.
  • 19. Sanofi SA
  • 20. Sensorion SA
  • 21. Siemens Healthineers AG
  • 22. Smith & Nephew PLC
  • 23. Sonova Holding AG
  • 24. Sound Pharmaceuticals, Inc.
  • 25. Starkey Laboratories, Inc.
  • 26. Stryker Corporation
  • 27. Sun Pharmaceutical Industries Limited
  • 28. Teva Pharmaceutical Industries Limited
  • 29. Viatris Inc.
  • 30. Widex A/S
  • 31. WS Audiology A/S
  • 32. Zounds Hearing

LIST OF FIGURES

  • FIGURE 1. ENT DISORDER TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. ENT DISORDER TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. ENT DISORDER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. ENT DISORDER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ENT DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ENT DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENT DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENT DISORDER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY MASTOIDECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY STAPEDECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TYMPANOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY VESTIBULAR REHABILITATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY MENIERE'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY OTITIS EXTERNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NASAL POLYPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY PHARYNGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY TONSILLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY HEARING AID DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY HEARING IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY NASAL SPLINTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY VOICE PROSTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY ENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY REHABILITATION CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ENT DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES ENT DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA ENT DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. EGYPT ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY EAR, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY NOSE, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY THROAT, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 334. FINLAND ENT DISORDER TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ENT DISORDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ENT DISORDER TREATMENT MARKET SIZE